News
DVAX
--
0.00%
--
Dynavax (DVAX) Up as EMA Accepts Valneva's COVID-19 Vaccine MAA
Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.
Zacks · 4h ago
Dynavax to Present at the H.C. Wainwright Global Investment Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Global Investm...
PR Newswire · 4d ago
110 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.
Benzinga · 4d ago
Here's why meme stocks are hinting at another flashy rally for `junk stocks`
We've seen this movie before only to watch dip-buyers get fleeced — but money managers are now warming to the idea of a material bounce in stocks.
Yahoo Finance · 05/13 20:17
Hot Stocks: DUOL rises on earnings; BRLT drops; Buffett buys more OXY shares; DVAX added to index
Earnings news once again stirred trading in Friday's midday action. Duolingo (NASDAQ:DUOL) jumped almost 40% on better-than-expected results. Meanwhile, Brilliant Earth Group (BRLT) lost more than a quarter of its
Seekingalpha · 05/13 16:42
RIOT, MARA and DM among pre market gainers
Robinhood Markets (HOOD) +23% Bitcoin rebounds with rally above $30,000, but concerns remain. Endeavor Group Holdings (EDR) +20% on Q1 results. Molecular Partners (MOLN) +19% on Q1 results. Celularity (CELU) +18%. Coinbase Global (COIN) +14% Robinhood Mark...
Seekingalpha · 05/13 12:32
Dynavax Tech, Alpha and Omega Semiconductor trade high on addition to the S&P SmallCap 600
S&P Dow Jones Indices announced that it will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Dynavax Technologies (DVAX) will replace Bottomline Technologies (EPAY) in the S&P
Seekingalpha · 05/13 11:23
Sector Update: Health Care
MT Newswires · 05/13 09:12
I'm Giving Dynavax Another Shot -- a Booster Shot
Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.
TheStreet.com · 05/08 11:31
Dynavax Technologies (DVAX) Misses Q1 Earnings and Revenue Estimates
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -8.33% and 3.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 22:05
Dynavax Technologies Q1 EPS $0.26 Beats $0.24 Estimate, Sales $114.00M Miss $154.30M Estimate
Dynavax Technologies (NASDAQ:DVAX) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.24 by 8.33 percent. This is a 2500 percent increase over earnings of $0.01 per share from
Benzinga · 05/05 21:05
Dynavax GAAP EPS of $0.26 beats by $0.02, revenue of $114M misses by $40.29M
Dynavax press release (NASDAQ:DVAX): Q1 GAAP EPS of $0.26 beats by $0.02. Revenue of $114M (+36.8% Y/Y) misses by $40.29M. CpG 1018 adjuvant net product revenue of $91.5M, up 23%
Seekingalpha · 05/05 20:06
-- Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q1 Revenue $114M, vs. Street Est of $154.3M
MT Newswires · 05/05 16:16
Dynavax's Adjuvant-Based Bivalent COVID-19 Vaccine Candidate Shows Encouraging Preclinical Action
Benzinga · 05/05 16:08
Clover’s Bivalent COVID-19 Vaccine Candidate Demonstrates Broad Neutralization Against Omicron and Other Variants of Concern
-- Bivalent candidate (Prototype + Omicron) demonstrates broad neutralization against Omicron and all VoCs in both primary vaccination and booster settings in preclinical study -- -- Potential to pursue licensure pathway based on immuno-bridging to prototy...
GlobeNewswire · 05/05 11:00
While shareholders of Dynavax Technologies (NASDAQ:DVAX) are in the black over 5 years, those who bought a week ago aren't so fortunate
While Dynavax Technologies Corporation ( NASDAQ:DVAX ) shareholders are probably generally happy, the stock hasn't had...
Simply Wall St. · 05/03 11:20
Valneva slips as EU regulators request more data on COVID-19 shot
The ADRs of Valneva (NASDAQ:VALN) have lost ~17% in the premarket Monday after the French biotech announced on Monday that the European Medicines Agency (“EMA”) requested additional data to support the marketing
Seekingalpha · 04/25 13:15
Dynavax to Report First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, will report first quarter 2022 financial results on Thursday, May 5, 2022, after the U.S. financial...
PR Newswire · 04/21 20:05
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted restricted stock units (RSUs) covering an aggregate of 28,250 shares of Dynavax common stock as inducements to 5 newly-hired employees in connection with commencement of emp...
PR Newswire · 04/05 20:02
Dynavax Technologies Corporation's (NASDAQ:DVAX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Dynavax Technologies (NASDAQ:DVAX) has had a rough three months with its share price down 20%. But if you pay close...
Simply Wall St. · 04/03 18:55
Webull provides a variety of real-time DVAX stock news. You can receive the latest news about Dynavax Technolo through multiple platforms. This information may help you make smarter investment decisions.
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The Company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). It is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), pertussis, and universal influenza.